Commentary

Blog: Front and Center – Injectables and the Nose


 

It's right smack in the middle of the face, but, until now, I had not even considered injectables could be used to enhance the appearance of the nose.

Botulinum toxin for wrinkles on the forehead – seen it. Use of fillers to smooth out facial lines – watched it. Lip enhancement – heard it. But recontouring the nose? Never.
Photo credit: Damian McNamara

Dr. Vince Bertucci (left) and Dr. Jean- François Tremblay (right).

"We are not going to replace rhinoplasty, but there is a lot we can do with fillers in an in-and-out procedure," said Dr. Vince Bertucci, Immediate Past President of the Canadian Society for Dermatologic Surgery and the Medical Director of Bertucci MedSpa in Woodbridge, just outside Toronto. For example, we can make the bridge of the nose more prominent, relax the "bunny lines" a patient gets when they smile, and make a nose less "droopy" at the tip, he said.

Nonsurgical rhinoplasty has its advantages, Dr. Jean-François Tremblay said. Injectables "can be used to see if a patient likes the changes to their nose before making the changes permanent." And, although results are not as dramatic, they avoid the often significant downtime, swelling, and pain associated with a traditional "nose job," said Dr. Tremblay, a dermatologic surgeon in Outremont, Que., Canada.

Filler and/or botulinum toxin enhancements are less expensive. Also, unlike surgery, many filler corrections can be reversed or modified, Dr. Tremblay added. On the downside, the effects don't last forever. Also, "you can only add volume and not remove anything."

Many patients unhappy with their nose appearance do not know injectables are an option, commented a dermatologic surgeon attending this session at the ASDS/ASCDAS joint annual meeting in Chicago. Dr. Tremblay agreed, and said more patient education is needed.

Dr. Bertucci receives honoraria from Allergan and is a consultant for Procter & Gamble. Dr. Tremblay is a medical consultant for Allergan, Medicis, Canderm Pharma, LaRoche-Posay, Procter & Gamble, and Johnson & Johnson.

–Damian McNamara

@MedReporter on Twitter

Recommended Reading

EADV: Cutaneous Lupus Linked to Increased Skin Cancer Risk
MDedge Dermatology
Violent TV, Videos Appear to Desensitize Boys to Aggression
MDedge Dermatology
EADV: Leukemia Patients Predisposed to Aggressive Melanoma
MDedge Dermatology
Never Say Never: Surgical Errors Remain a Concern
MDedge Dermatology
While I Have You
MDedge Dermatology
Fat Transfer Boosts HIV Patients' Quality of Life
MDedge Dermatology
FDA Regulators Losing Patience With "Well Tolerated" Drug Claims
MDedge Dermatology
India's Malaria Deaths Grossly Underestimated
MDedge Dermatology
MelaFind Device Surpassed Dermatologists in Identifying Melanoma
MDedge Dermatology
U.S. Workers Paying More, Getting Less Health Coverage
MDedge Dermatology